Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK

被引:45
作者
Duggan, A
Warner, J
Knapp, M
Kerwin, R
机构
[1] Abacus Int, Bicester OX26 6AA, Oxon, England
[2] Inst Psychiat, London, England
关键词
D O I
10.1192/bjp.182.6.505
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Schizophrenia is a major cause of suicide, and symptoms characteristic of treatment-resistant disease are strong risk factors. Clozapine reduces symptoms in 60% of such patients and significantly decreases the risk of suicide. Aims To model the impact of increased clozapine prescribing on lives saved and resource utilisation. Method A model was built to compare current levels of clozapine prescribing with a scenario in which all suitable patients with treatment-resistant schizophrenia received clozapine. Results It was estimated that an average of 53 lives could be saved in the UK each year. If clozapine is cost-neutral, the cost per life-year saved is pound5108. If clozapine achieves a 10% reduction in annual support costs, the net saving is pound8.7 million per annum. An average of 167 acute beds would be freed each year. Conclusions The use of clozapine in treatment-resistant schizophrenia saves lives, frees resources and is cost-effective.
引用
收藏
页码:505 / 508
页数:4
相关论文
共 21 条
[1]  
ADAMS C, 1999, DRUG TREATMENTS SCHI
[2]   ATTEMPTED-SUICIDE AND DEPRESSION IN SCHIZOPHRENIA [J].
ADDINGTON, DE ;
ADDINGTON, JM .
ACTA PSYCHIATRICA SCANDINAVICA, 1992, 85 (04) :288-291
[3]   Cost-effectiveness of clozapine - A UK clinic-based study [J].
Aitchison, KJ ;
Kerwin, RW .
BRITISH JOURNAL OF PSYCHIATRY, 1997, 171 :125-130
[4]  
[Anonymous], SAFER SERVICES NATL
[5]  
[Anonymous], CM4386
[6]  
[Anonymous], UNIT COSTS HLTH SOCI
[7]   ASSESSMENT OF COSTS AND BENEFITS OF DRUG-THERAPY FOR TREATMENT-RESISTANT SCHIZOPHRENIA IN THE UNITED-KINGDOM [J].
DAVIES, LM ;
DRUMMOND, MF .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 162 :38-42
[8]  
*DEP HLTH, 1996, HOSP EP STAT
[9]   Cost of schizophrenia to UK society - An incidence-based cost-of-illness model for the first 5 years following diagnosis [J].
Guest, JF ;
Cookson, RF .
PHARMACOECONOMICS, 1999, 15 (06) :597-610
[10]   Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study [J].
Knapp, M ;
Chisholm, D ;
Leese, M ;
Amaddeo, F ;
Tansella, M ;
Schene, A ;
Thornicroft, G ;
Vazquez-Barquero, JL ;
Knudsen, HC ;
Becker, T .
ACTA PSYCHIATRICA SCANDINAVICA, 2002, 105 (01) :42-54